Becaplermin is a recombinant human platelet-derived growth factor (PDGF) used primarily in the treatment of diabetic ulcers. It is a protein that promotes wound healing by stimulating cell proliferation, migration, and angiogenesis. The substance is characterized by its ability to enhance the healing process in chronic wounds, particularly in patients with diabetes. Becaplermin is typically administered topically as a gel, and its efficacy is often evaluated in conjunction with standard wound care practices. The mechanism of action involves binding to PDGF receptors on target cells, leading to various cellular responses that facilitate tissue repair. It is important to note that becaplermin is associated with specific safety considerations, including the potential for tumorigenesis in patients with certain risk factors, which necessitates careful patient selection and monitoring during treatment. Overall, becaplermin represents a significant advancement in regenerative medicine, particularly for individuals suffering from difficult-to-heal wounds.

Becaplermin

165101-51-9: Becaplermin is a recombinant human platelet-derived growth factor (PDGF) used primarily in the treatment of diabetic ulcers. It is a protein that promotes wound healing by stimulating cell proliferation, migration, and angiogenesis. The substance is characterized by its ability to enhance the healing process in chronic wounds, particularly in patients with diabetes. Becaplermin is typically administered topically as a gel, and its efficacy is often evaluated in conjunction with standard wound care practices. The mechanism of action involves binding to PDGF receptors on target cells, leading to various cellular responses that facilitate tissue repair. It is important to note that becaplermin is associated with specific safety considerations, including the potential for tumorigenesis in patients with certain risk factors, which necessitates careful patient selection and monitoring during treatment. Overall, becaplermin represents a significant advancement in regenerative medicine, particularly for individuals suffering from difficult-to-heal wounds.

CAS 165101-51-9

Becaplermin